Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Vipshop Holdings Ltd - ADR (VIPS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Vipshop Holdings Ltd - ADR — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $298.3 (market cap $8.04B), while Vipshop Holdings Ltd - ADR trades at $13.43 (market cap $6.66B). The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is the larger of the two by market cap, and Vipshop Holdings Ltd - ADR pays a 4.47% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | VIPS | |
|---|---|---|
Market Cap | $8.04B | $6.66B |
Sector | Health | Consumer Cyclical |
52-Week High | $339.75 | $20.68 |
52-Week Low | $241.71 | $12.92 |
Enterprise Value | $7.85B | $3.25B |
Dividend Yield | — | 4.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
Vipshop Holdings (VIPS) trades at $13.92, down slightly by 0.14% on the day, with a bullish technical signal supported by strong ADX readings. The stock presents attractive valuation metrics with a P/E of 6.35 and P/S of 0.45, while maintaining solid profitability with an 18.43% ROE. Recent Q1 2026 earnings matched expectations, and the company is pursuing growth through outlet store spin-offs into a REIT structure.
The outlook remains positive given deep value multiples and analyst consensus leaning buy, though risks include revenue pressure from a later Chinese New Year and competitive e-commerce headwinds. Upside potential hinges on execution of the outlet strategy and return to sustained revenue growth in FY2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Vipshop Holdings Ltd - ADR
Vipshop Holdings Ltd is an online discount retailer for brands in China. The company offers branded products to consumers in China through flash sales on its vipshop.com, vip.com and lefeng.com websites. Flash sales represent an online retail format combining the advantages of e-commerce and discount sales through selling a finite quantity of discounted products or services online for a limited period of time. It deals in a wide range of products and services for consumers specializing in branded cosmetics, apparel, healthcare products, food and other consumer products. Its operating segment includes Vip.com and Shan Shan Outlets. The company generates maximum revenue from Vip.com segment.
Read more on VIPS →
